6HL0:F:F-R1 RCM Inc (EUR)

COMMON STOCK | Health Information Services |

Last Closing

USD 12.7

Change

+0.10 (+0.79)%

Market Cap

USD 5.45B

Volume

350.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance. R1 RCM Inc. was formerly known as Accretive Health, Inc. and changed its name to R1 RCM Inc. in January 2017. The company was incorporated in 2003 and is headquartered in Murray, Utah.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
L0T:F GE HEALTHCARE TECH.INC.

+1.53 (+1.93%)

USD 35.91B
2HE:F Healthequity Inc

-1.00 (-1.42%)

USD 6.16B
4YC:F M3 INC.

+0.10 (+1.15%)

USD 5.81B
9EH:F Evolent Health Inc

+0.40 (+1.46%)

USD 3.16B
1KJ:F 10X GENOMICS DL -00001

+2.23 (+11.83%)

USD 2.31B
6JM:F JMDC INC.

N/A

USD 1.93B
OC9:F Omnicell Inc

-1.80 (-4.50%)

USD 1.78B
19P:F Phreesia Inc

-0.20 (-0.92%)

USD 1.26B
4LL:F Teladoc Inc

+0.05 (+0.60%)

USD 1.25B
1XZ:F Ping An Healthcare and Technol..

+0.02 (+1.57%)

USD 1.21B

ETFs Containing 6HL0:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 32.98% 83% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.98% 80% B- 78% C+
Trailing 12 Months  
Capital Gain -12.41% 61% D- 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.41% 58% F 30% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.83% 58% F 26% F
Dividend Return -7.83% 55% F 24% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.02% 92% A 86% B+
Risk Adjusted Return -71.09% 30% F 15% F
Market Capitalization 5.45B 95% A 79% B-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.